Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
Mikael EbboAurélie GradosMaxime SamsonMatthieu GrohAnderson LoundouAude RigoletBenjamin TerrierConstance GuillaudClarisse Carra-DallièreFrédéric RenouAgnieszka PozdzikPierre LabaugeSylvain PalatJean-Marie BerthelotJean-Loup PennaforteAlain WynckelCéline LebasNoémie Le GouellecThomas QuémeneurKarine DahanFranck CarbonnelGaëlle LerouxAntoinette PerlatAlexis MathianPatrice CacoubEric HachullaNathalie Costedoat-ChalumeauJean-Robert HarléNicolas SchleinitzPublished in: PloS one (2017)
RTX is effective for both induction therapy and treatment of relapses in IgG4-RD, but relapses are frequent after B-cell reconstitution. Maintenance therapy with systematic RTX infusions is associated with longer relapse-free survival and might represent a novel treatment strategy. Yet, the high rate of infections and the temporary effect of RTX might be hindrances to such strategy.